Compare CMMB & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMMB | SGLY |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 8.5M |
| IPO Year | 2023 | 2008 |
| Metric | CMMB | SGLY |
|---|---|---|
| Price | $1.08 | $0.36 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 102.3K | ★ 435.4K |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $1,693,264.00 |
| Revenue This Year | N/A | $2,964.44 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.01 | $0.23 |
| 52 Week High | $3.44 | $8.65 |
| Indicator | CMMB | SGLY |
|---|---|---|
| Relative Strength Index (RSI) | 24.22 | 26.07 |
| Support Level | N/A | $0.23 |
| Resistance Level | $1.89 | $2.15 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 5.36 | 4.60 |
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.